Skip to main content
SpringerLink
Log in

Tenofovir Disoproxil Fumarate

Clinical Pharmacology and Pharmacokinetics

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Tenofovir disoproxil fumarate (tenofovir DF) is an oral prodrug of tenofovir, a nucleotide (nucleoside monophosphate) analogue with activity against retroviruses, including HIV-1, HIV-2 and hepadnaviruses. Following absorption, tenofovir DF is rapidly converted to tenofovir, which is metabolised intracellularly to its active anabolite tenofovir diphosphate, which is a competitive inhibitor of HIV-1 reverse transcriptase and terminates the growing DNA chain. Tenofovir exerts antiviral effects in a variety of cell types, including resting cells.

Tenofovir exhibits longer serum (17 hours) and intracellular (≥60 hours) half-lives than those of nucleoside analogues, which supports a flexible once-daily administration schedule. The pharmacokinetics of tenofovir are dose-proportional and similar in healthy volunteers and HIV-infected individuals. The oral bioavailability of tenofovir is enhanced by administration with a high-fat meal, but is similar at steady state when administered with or without a typical meal.

Tenofovir is not a substrate, inducer or inhibitor of human cytochrome P450 enzymes in vitro or in vivo. Tenofovir DF has been studied with 15 other antiretroviral and other concomitant medications frequently used in the HIV-1-infected population. With the exception of didanosine and atazanavir, which require dosage modifications, no clinically significant drug interactions have been observed with tenofovir DF.

The recommended oral dosage of tenofovir DF in adults is 300 mg/day. Tenofovir is eliminated by renal elimination, including tubular secretion; dose-interval adjustments are necessary for tenofovir DF in patients with significant renal impairment. No dosage adjustment of tenofovir DF is necessary in patients with liver disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Table I
Table II
Table III
Fig. 6
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002 Jun 14; 16(9): 1257–63

    Article  PubMed  CAS  Google Scholar 

  2. Squires K, Pozniak AL, Pierone Jr G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Intern Med 2003 Sep 2; 139 (5 Pt 1): 313–21

    PubMed  CAS  Google Scholar 

  3. Staszewski S, Gallant JE, Pozniak AL, et al. Favorable metabolic profile for tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week interim results [abstract]. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; 2003 Jul 13–16; Paris

    Google Scholar 

  4. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003; 17(8): 1151–6

    Article  PubMed  CAS  Google Scholar 

  5. Shaw J-P, Sueoka CM, Oliyai R, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[R)-2-(phosphonomethoxy)propyl]denine (PMPA) in dogs. Pharm Res 1997 Dec; 14(12): 1824–9

    Article  PubMed  CAS  Google Scholar 

  6. Van Gelder J, Deferme S, Naesens L, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002 Aug; 30(8): 924–30

    Article  PubMed  Google Scholar 

  7. Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998 Mar; 42(3): 612–7

    PubMed  CAS  Google Scholar 

  8. Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxy-carbonyloxymethyl)-9-(2-phosphonylmethoxypropyl) adenine in mice. Antimicrob Agents Chemother 1998 Jul; 42(7): 1568–73

    PubMed  CAS  Google Scholar 

  9. Cundy KC, Sueoka CM, Lynch GR, et al. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[R)-2-(phosphonomethoxy)propyl]denine (PMPA) in dogs. Antimicrob Agents Chemother 1998 Mar; 42(3): 687–90

    PubMed  CAS  Google Scholar 

  10. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steadystate pharmacokinetics of tenofovir DF in HIV-infected children. Antimicrob Agents Chemother 2003 Jan; 48(1): 124–9

    Article  Google Scholar 

  11. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel antihumanimmunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998 Sep; 42(9): 2380–4

    PubMed  CAS  Google Scholar 

  12. Naesens L, Baizarini J, Bischofberger N, et al. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloylox-ymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyoxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 1996 Jan; 40(1): 22–8

    PubMed  CAS  Google Scholar 

  13. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother 2001 Oct; 45(10): 2733–9

    Article  PubMed  CAS  Google Scholar 

  14. Pozniak AL, Plettenberg A, Rozenbaum W, et al. Tenofovir DF: a 24-week interim analysis from a phase III randomized, double blind, placebo controlled study in antiretroviral experienced patients [abstract]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28–31; Athens

    Google Scholar 

  15. Hawkins T, Veikley W, St Claire R, et al. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens [oral presentation]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  16. Kearney BP, Damle B, Plummer A, et al. Pharmacokinetic evaluation of tenofovir DF and enteric-coated didanosine. XIV International AIDS Conference; 2002 Jul 7–12; Barcelona

    Google Scholar 

  17. Gilead Sciences Inc. Tenofovir disoproxil fumarate (Viread®) tablets: prescribing information. Foster City (CA): Gilead Sciences Inc., 2003 Oct

    Google Scholar 

  18. Kearney BP, Gill SC, Flaherty JF, et al. Effect of demographic variables on the pharmacokinetics of tenofovir DF in HIV-infected patients and healthy subjects [poster]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago

    Google Scholar 

  19. Kearney BP, Liaw S, Yale K, et al. Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment [poster]. Sixth International Congress on Drug Therapy in HIV Infection; 2002 Nov 17–21; Glasgow

    Google Scholar 

  20. Kearney BP, Benhamou Y, Flaherty J, et al. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis [poster]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

    Google Scholar 

  21. Flaherty JF, Kearney BP, Wolf JJ, et al. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir [poster]. The 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

    Google Scholar 

  22. Kearney BP, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir [poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

    Google Scholar 

  23. Kearney BP, Flaherty JF, Sayre JR, et al. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and lamivudine or didanosine. The 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

    Google Scholar 

  24. Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine and dose reduction [poster]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston

    Google Scholar 

  25. Kaul S, Damle B, Bassi K, et al. Pharmacokinetic evaluation of reduced doses of didanosine enteric coated capsules (ddI-EC) in combination with tenofovir disoproxil fumarate (TDF) and food for a once-daily antiretroviral regimen [poster]. 4th International Workshop on Clinical Pharmacology of HIV Therapy; 2003 Mar 27–29; Cannes

    Google Scholar 

  26. Ray A, Olson L, Fridland A. Mechanism of the drug interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir or tenofovir [poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  27. Ray A, Olson L, Fridland A. Role of purine nucleoside Phosphorylase in drug interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir or tenofovir. Antimicrob Agents Chemother 2004 Apr; 48(4): 1089–95

    Article  PubMed  CAS  Google Scholar 

  28. Flaherty J, Kearney B, Wolf J, et al. Coadministration of tenofovir DF and didanosine: a pharmacokinetic and safety evaluation [poster]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago

    Google Scholar 

  29. Kearney BP, Flaherty JF, Wolf JJ, et al. Coadministration of tenofovir DF and didanosine: pharmacokinetic drug-drug interaction and safety evaluation [poster 172]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001 Oct 28–31; Athens

    Google Scholar 

  30. Robbins BL, Wilcox CK, Fridland A, et al. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003 Jun; 23(6): 695–701

    Article  PubMed  CAS  Google Scholar 

  31. Blum MR, Begley J, Zong J, et al. Lack of a pharmacokinetic interaction between emtricitabine and tenofovir DF when coadministered to steady state in healthy volunteers [poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

    Google Scholar 

  32. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: March 23, 2004 [online]. Available from URL: http://aidsinfo.nih.gov/guidelines/default_db2.as-p?.id=50 [Accessed 2004 May 31]

  33. Kearney BP, Zong J, Begley J, et al. Bioequivalence of combination tenofovir DF/emtricitabine tablets for one-pill once daily administration [poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  34. Kaul S, Bassi K, Damle B, et al. Stavudine extended release formulation (D4T XR) and tenofovir disoproxil fumarate (TDF): lack of a pharmacokinetic (PK) drug interaction [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

    Google Scholar 

  35. Kaul S, Bassi K, Damle B, et al. Lack of interaction between stavudine extended release formulation (d4T XR) and tenofovir disoproxil fumarate (TDF) [abstract]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston

    Google Scholar 

  36. Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analogue, are not affected by tenofovir DF [poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

    Google Scholar 

  37. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients [abstract]. Antivir Ther 2003; 8 Suppl. 1: S195

    Google Scholar 

  38. Gallant JE, Rodriguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis [oral presentation]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

    Google Scholar 

  39. Ray A, Vela JE, Olson L, et al. Lack of interaction between tenofovir and abacavir in human cells [poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  40. Kearney BP, Flaherty JF, Wolf J, et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir/ritonavir in healthy subjects [poster]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001 Oct 28–31; Athens

    Google Scholar 

  41. DeJesus E, Grinsztejn B, Rodriguez C, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs lopinavir/ritonavir (LPV/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS AI424-045 [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

    Google Scholar 

  42. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naîve patients: 48-week results [poster]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

    Google Scholar 

  43. US Department of Health and Human Services. Important new pharmacokinetic data for Reyataz™ (atazanavir sulfate) in combination with Viread® (tenofovir disoproxil fumarate) [press release, 2003 August 8] [online]. Available from URL: http://aidsinfo.nih.gov/aprs/aprs_press.asp?an=A00678 [Accessed 2004 Jun 8]

  44. Chiu Y-L, Foit C, Gathe J, et al. Multiple-dose pharmacokinetics and initial antiviral effect of once daily lopinavir/ritonavir (LPV/r) in combination with tenofovir (TDF) and emtricitabine (FTC) in HIV-infected antiretroviral-naîve subjects (study 418) [poster]. Second IAS Conference on HIV Pathogenesis and Treatment; 2003 Jul 13–16; Paris

    Google Scholar 

  45. Kaul S, Bassi K, Damle, et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

    Google Scholar 

  46. Kruse G, Stocker H, Breske A, et al. Trough levels of seven different atazanavir regimens in HIV-infected patients [poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  47. Taburet A-M, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004 Jun; 48(6): 2091–6

    Article  PubMed  CAS  Google Scholar 

  48. Bristol-Myers-Squibb, Inc. Atazanavir FDA Advisory Committee background document [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_BristolMyersSquibb-Atazanavir.pdf [Accessed 2004 Jun 8]

  49. Boffito M, D’Avolio A, Di Perri G, et al. Repeated pharmacokinetics of tenofovir disoproxil fumarate (TDF) in HIV-infected adults receiving saquinavir (SQV) hard gel/ritonavir (RTV) 1000/l00mg BID [poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  50. Ananworanich J, Siangphoe U, Mahanontharit A, et al. Saquinavir Crmin before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100mg [poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  51. Smith P, Kearney BP, Cloen D, et al. Tenofovir DF does not affect the pharmacokinetics of pharmacodynamics of methadone. Pharmacotherapy. In press

  52. Kearney BP, Isaacson E, Sayre J, et al. Tenofovir DF (TDF) and norgestimate/ethinyl estradiol: lack of pharmacokinetic drug interaction [poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

    Google Scholar 

  53. Droste JAH, Kearney BP, Horssen P, et al. Lack of clinically relevant interaction between tenofovir DF and rifampin in healthy volunteers [poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

    Google Scholar 

  54. Izzedine H, Isnard-Bagnis C, Hulot J-S, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004 Apr 20; 18(7): 1074–6

    Article  PubMed  CAS  Google Scholar 

  55. Squires K, Pozniak AL, Pierone G, et al. Tenofovir DF in antiretroviral-experienced, nucleoside-resistant HIV-1 infected patients with incomplete viral suppression. Ann Intern Med 2003; 139(5): 313–20

    PubMed  CAS  Google Scholar 

  56. Gallant JE, Pozniak AL, Staszewski S, et al. Similar 96 week renal safety profile of tenofovir disoproxil fumarate vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral-naîve patients [poster H-840]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

    Google Scholar 

  57. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16(9): 1257–63

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

All authors are employees of Gilead Sciences, Inc.

Author information

Authors and Affiliations

  1. Gilead Sciences, Inc., Foster City, California, USA

    Brian P. Kearney, John F. Flaherty & Jaymin Shah

Authors
  1. Brian P. Kearney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John F. Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaymin Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian P. Kearney.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kearney, B.P., Flaherty, J.F. & Shah, J. Tenofovir Disoproxil Fumarate. Clin Pharmacokinet 43, 595–612 (2004). https://doi.org/10.2165/00003088-200443090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200443090-00003

Keywords

Search

Navigation